Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy

Wei M., Wang D., Xu W., Zang X., Jiang J.

Narrative Review on Face & Skin, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Nanomedicine (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41773242
PMCID
PMC12949809
DOI
10.2147/ijn.s583756
Citations
1

Abstract (original English)

Exosomes are membrane-bound vesicles secreted by almost all types of cells, including but not limited to immune cells, neurons, epithelial cells, and cancer cells. Exosomes carry DNA, RNA, lipids, metabolites, as well as cytoplasmic and cell surface proteins. Their role in cancer progression is dynamic and is related to the type of cancer, genetics, and stage. At the same time, exosomes have attracted widespread attention as key mediators of intercellular communication in the tumor immune microenvironment (TME). This comprehensive review delineates the pleiotropic roles of exosomes in tumor immunobiology, emphasizing their bimodal capacity to either foster immunosuppression or potentiate antitumor immunity. We systematically synthesize recent advancements in exosome-based immunotherapeutic regimens, with particular emphasis on their synergistic efficacy when integrated with established modalities, namely immune checkpoint blockade and adoptive cellular therapy. Furthermore, we critically appraise emergent technologies for exosome isolation and characterization, underscoring their transformative implications for liquid biopsy platforms in real-time immune surveillance and the development of predictive biomarkers. This review posits exosome-centric strategies as a paradigm-shifting frontier in precision immuno-oncology, furnishing innovative remedies for recalcitrant therapeutic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansNeoplasmsImmunotherapyCell CommunicationExosomesTumor MicroenvironmentBiomarkers, TumorLiquid Biopsy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research